

<sup>3</sup> *Becada de Gastroenterología, Departamento de Medicina, Sección Gastroenterología, Hospital Clínico Universidad de Chile, Escuela de Medicina Universidad de Chile, Santiago, Chile*

<sup>4</sup> *Tesista Magister Sociología, Pontificia Universidad Católica de Chile, Santiago, Chile*

**Introduction:** Hospitalizations (H) and mortality by alcoholic hepatitis (AH) have increased in Europe and North America. In Chile we do not have published data.

**Objectives:** To describe the trend in H and mortality of hospitalized patients with AH in Chile.

**Methods:** Descriptive analysis of combination of cross-sections and regression models (STATA 15). Population data from MINSAL-DEIS 2001-2018 hospital discharge databases (HD) were used. HD by AH were identified by ICD-10 code K701.

**Results:** Between 2001-2018 there were 5,678 HD per AH. Average age 50 years. The rate of HD per AH per million inhabitants increased from 12.8 in 2001 to 18.5 in 2018 (44%). A linear estimate suggests that the rate increases by 0.55 points per year. In the population of 20-40 years it stands out that in women it increased by 64%. The only group where the rate of HD per AH increase steadily over time (in the rest the increase was less and less). The proportion by sex remained stable in 83% men and 17% women. In both sexes, 10% HD deceased, although in men a clear upward trend is observed (+0.32% annually, with a minimum of 6.5% HD in 2001 and a maximum of 15.3% HD in 2017), while in women the upward trend shows fluctuations.

**Conclusions:** In Chile in recent years there has been an increase in HD by AH. This increased incidence is reflected in higher mortality in patients hospitalized for AH. The increase in HD was more stable among women aged 20-40 years.

<https://doi.org/10.1016/j.aohep.2021.100426>

#### **P-64 THE ALCOHOL-ASSOCIATED LIVER DISEASE PARADOX IN CHILE: AN ASSESSMENT WITH DATA FROM THE NATIONAL HEALTH SURVEY (ENS 2016-2017)**

Gianfranco Oneto<sup>1</sup>, Luis Antonio Díaz<sup>2</sup>, Francisco Idalsoaga<sup>2</sup>, Juan Pablo Arab<sup>2</sup>, Pablo Roblero<sup>3</sup>, Maximo Cattaneo<sup>4</sup>, Alvaro Urzua<sup>4</sup>, Jaime Poniachik<sup>4</sup>, Juan Pablo Roblero<sup>4</sup>

<sup>1</sup> *Department of Gastroenterology, Hospital Clínico San Borja Arriarán, Escuela de Medicina Universidad de Chile, Santiago, Chile*

<sup>2</sup> *Department of Gastroenterology, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile*

<sup>3</sup> *Tesista Magister Sociología, Pontificia Universidad Católica de Chile, Santiago, Chile*

<sup>4</sup> *Department of Gastroenterology, Hospital Clínico Universidad de Chile, Escuela de Medicina Universidad de Chile, Santiago, Chile*

**Introduction:** It has been observed people with low-income-level (<IL) have greater liver injury due to alcohol consumption (AC), even when their consumption levels are lower or equal to those with high-income-level (>IL). The aim of this study was to evaluate alcohol-associated liver disease (ALD) paradox in Chile.

**Methods:** With data from the ENS 2016-17 (N=2,190; age 25-64) we constructed a logit regression model that estimated the effect hazardous AC (AUDIT $\geq$ 8) on the probability of presenting ALD (GPT $\geq$ 40 U/L). We focus on the interaction between hazardous AC

and IL, controlling for the presence of metabolic syndrome (MS), diabetes mellitus (T2DM), obesity and tobacco.

**Results:** The average AC was 39g of alcohol per week (13g women <IL; 23g women >IL; 64g men, without differences by IL). In women, hazardous AC only increased ALD among those >IL who presented with obesity or MS in combination with T2DM (+36% obesity+MS +T2DM; p<0.01). In men, hazardous AC only increased ALD among those with <IL (16% without comorbidities, 17% with tobacco, 22% with MS, 26% with obesity, and 28% with all; p<0.05).

**Conclusion:** ALD paradox can be observed in Chile among men, but not among women. The evaluated associated comorbidities increased the effect of hazardous AC on ALD. It is necessary to investigate how the IL determines the patterns of AC and comorbidities. Among men, <IL is likely to be associated with more harmful drinking patterns and a greater presence of comorbidities. Among women, >IL is likely associated with higher AC and more harmful consumption patterns.

<https://doi.org/10.1016/j.aohep.2021.100427>

#### **P-65 CONCORDANCE OF FIB-4 WITH TRANSITION ELASTOGRAPHY IN THE DIAGNOSIS OF ADVANCED LIVER FIBROSIS**

Juan Francisco Rozas, Katherine González, Camila Estay, Maximo Cattaneo, Alvaro Urzúa, Juan Pablo Roblero, Alexandra Sandoval, Jaime Poniachik

*Servicio de Gastroenterología, Hospital Clínico de la Universidad de Chile, Santiago, Chile*

**Introduction:** Transient elastography (TE) and non-invasive scores such as FIB-4 are non-invasive methods to evaluate liver fibrosis.

**Objectives:** To evaluate the concordance between TE and FIB-4 in the diagnosis of advanced fibrosis.

**Methods:** Observational study. 185 patients (53  $\pm$  14 years, 71.4% women) referred for TE (FibroScan, Echosens). The main indication was non-alcoholic fatty liver disease (46%). Fibrosis staging sections recommended by the manufacturer were used. Clinical data and laboratory tests performed in the 30 days prior to the study were recorded. FIB-4 cuts > 3.45 and <1.45 were used to include and exclude advanced fibrosis, respectively. Statistical analysis by proportion of agreement and kappa index.

**Results:** 26 cases (14.1%) presented advanced fibrosis (F3-F4) according to TE. The proportion according to FIB-4 was 89%, with a kappa index of 0.43. 93.8% of the patients with FIB-4 without advanced fibrosis had a concordant TE evaluation (F0-F2). 59 cases (31.9%) obtained an indeterminate FIB-4 value, of which 52.5%, 30.5% and 17% corresponded to patients without fibrosis, significant fibrosis and advanced fibrosis according to TE, respectively.

**Conclusion:** There is a good concordance between FIB-4 and TE to rule out advanced fibrosis. The FIB-4 does not allow an adequate categorization of the degree of fibrosis in approximately one third of the cases.

<https://doi.org/10.1016/j.aohep.2021.100428>

#### **P-66 COULD PROTEIN CONTENT OF URINARY EXTRACELLULAR VESICLES BE USEFUL TO DETECT CIRRHOSIS IN ALCOHOLIC LIVER DISEASE?**

E. Gonzalez<sup>1</sup>, M. Azkargorta<sup>2</sup>, C. Garcia-Vallicrosa<sup>1</sup>, J. Prieto-Elordui<sup>3</sup>, F. Elortza<sup>2</sup>, S. Blanco-Sampascual<sup>3</sup>, J.M. Falcon-Perez<sup>1,4,5</sup>

<sup>1</sup> *Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), Derio, Spain*

<sup>2</sup> *Proteomics Platform. Center for Cooperative Research in Biosciences (CIC Biogune), Basque Research and Technology Alliance (BRTA), Derio, Spain*

<sup>3</sup> *Servicio de Aparato Digestivo, Hospital Universitario de Basurto, Bilbao Vizcaya, España*

<sup>4</sup> *Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain*

<sup>5</sup> *Ikerbasque Basque Foundation for Science Bilbao Spain*

**Introduction:** Alcohol abuse has a high impact on the mortality and morbidity related to a great number of diseases and is responsible for the development of alcoholic liver disease (ALD). It remains challenging to detect and evaluate its severity, which is crucial for prognosis.

**Objective:** In this work, we studied if urinary EVs (uEVs) could serve in diagnose and evaluate cirrhosis in ALD.

**Methods:** uEVs characterization by cryo-electron microscopy (Cryo-EM), Nanoparticle Tracking Analysis (NTA) and Western blotting (WB) was performed in a cohort of 21 controls and 21 cirrhotic patients. Then, proteomics of urinary EVs (uEVs) was carried out in a second cohort of 6 controls and 8 patients in order to identify new putative biomarkers for cirrhosis in ALD.

**Results:** uEVs concentration, size and composition were altered in cirrhotic patients. A total of 1304 proteins were identified in uEVs, and 90 of them were found to be altered in cirrhotic patients.

**Conclusions:** uEVs could be considered as a tool and a supplier of new biomarkers for ALD, whose application would be especially relevant in chronic patients. Yet, further research is necessary to obtain more relevant result in clinical terms.

<https://doi.org/10.1016/j.aohep.2021.100429>

### P-67 ULTRASOUND GUIDED TRANSIENT ELASTOGRAPHY FOR THE DIAGNOSIS AND STAGING OF LIVER FIBROSIS

Juan Francisco Rozas, Katherine González, Luis Salazar, Máximo Cattaneo, Juan Pablo Roblero, Alvaro Urzúa, Alexandra Sandoval, Jaime Poniachik

*Servicio de Gastroenterología, Hospital Clínico de la Universidad de Chile, Santiago, Chile*

**Introduction:** Transient elastography (TE) is a non-invasive method for the evaluation of liver fibrosis. Up to 20% of measurements fail, possibly due to the choice of probe position.

**Objectives:** To evaluate the use of ultrasound as a position guide (UPG) prior to TE to improve the measurement of liver stiffness (LS).

**Methods:** Prospective study of 237 patients (age 54 ± 14 years, 69% women) referred for TE (FibroScan, Echosens). The main indication was non-alcoholic fatty liver disease (52.3%). 65.4% of the patients were overweight or obese. LS was measured in each patient according to the manufacturer's recommendations and at the same appointment, in UPG. Fibrosis staging sections recommended by the manufacturer were used. Statistical analyzes performed with chi-square and t-test (p < 0.05).

**Results:** The mean LS with UPG was 7.6 (3.0-55.7) kPa. In 50 patients (21.1%) the measurement of LS failed without the use of ultrasound. There was not when using UPG. In the 187 patients with TE without ultrasound, IQR / LSM <10% was obtained in 67.3%. When UPG was used, it was obtained in 89% (p = 0.001). When comparing the fibrosis stage, in 21.4% of the cases it was modified when using

UPG; in 15% it changed from significant or advanced fibrosis (F2-F4) to non-significant (F0-F1), or vice versa.

**Conclusion:** The use of UPG before TE improved the success rate and reliability of the LS measurement, improving fibrosis staging.

<https://doi.org/10.1016/j.aohep.2021.100430>

### P-68 FREQUENCY AND FACTORS ASSOCIATED WITH ANTIBIOTIC DE-ESCALATION IN PATIENTS WITH CIRRHOSIS AND BACTERIAL INFECTIONS

Maria Nelly Gutierrez Acevedo<sup>1</sup>, Sabrina Barbero<sup>2</sup>, Lorena del Carmen Notari<sup>2</sup>, Marina Agozino<sup>3</sup>, Jose Luis Fernandez<sup>3</sup>, Silvina Tevez<sup>3</sup>, Maria Margarita Anders<sup>4</sup>, Nadia Grigera<sup>4</sup>, Florencia Antinucci<sup>4</sup>, Orlando Orozco Ganem<sup>4</sup>, Maria Dolores Murga<sup>5</sup>, Daniea Perez<sup>5</sup>, Ana Palazzo<sup>5</sup>, Liria Martinez Rejtman<sup>6</sup>, Ivonne Giselle Duarte<sup>7</sup>, Julio Vorobioff<sup>8</sup>, Victoria Trevizan<sup>8</sup>, Sofia Bulaty<sup>8</sup>, Fernando Bessone<sup>8</sup>, José Daniel Bosia<sup>9</sup>, Silvia Mabel Borzi<sup>9</sup>, Teodoro E. Stieben<sup>10</sup>, Adriano Masola<sup>10</sup>, Sebastian Eduardo Ferretti<sup>11</sup>, Agnel Ramos<sup>11</sup>, Diego Arufe<sup>12</sup>, Ezequiel Demirdjian<sup>12</sup>, Maria Pia Raffa<sup>12</sup>, Cintia Elizabet Vazquez<sup>13</sup>, Pablo Ruiz<sup>13</sup>, José Emanuel Martínez<sup>14</sup>, Hugo Fainboim<sup>15</sup>, Mirta Peralta<sup>15</sup>, Leandro Alfredo Heffner<sup>16</sup>, Andrea Odzak<sup>16</sup>, Andres Bruno<sup>16</sup>, Melisa Dirchwolf<sup>17</sup>, Jesica Tomatis<sup>17</sup>, Astrid Smud<sup>18</sup>, Manuel Mendizabal<sup>19</sup>, Josefina Pages<sup>19</sup>, Carla Bellizzi<sup>20</sup>, Ana Martinez<sup>20</sup>, Diego Giunta<sup>21</sup>, Marcelo Valverde<sup>22,23</sup>, Martin Elizondo<sup>22,23</sup>, Ezequiel Mauro<sup>24</sup>, Adrian Gadano<sup>21,24</sup>, Sebastián Marciano<sup>21,24</sup>

<sup>1</sup> *Clinica Chapelco, San Martin de los Andes, Argentina*

<sup>2</sup> *Hospital Churrucua Visca, CABA, Argentina*

<sup>3</sup> *Sanatorio Güemes, CABA, Argentina*

<sup>4</sup> *Hospital Aleman, CABA, Argentina*

<sup>5</sup> *Hospital A.C. Padilla, San Miguel de Tucuman, Argentina*

<sup>6</sup> *Hospital T J Schestakow, Mendoza, Argentina*

<sup>7</sup> *Hospital 4 de Junio, Sáenz Peña, Argentina*

<sup>8</sup> *Hospital Centenario, Rosario, Argentina*

<sup>9</sup> *Hospital Rossi, La Plata, Argentina*

<sup>10</sup> *Hospital San Martín, Paraná, Argentina*

<sup>11</sup> *Sanatorio Parque, Rosario, Argentina*

<sup>12</sup> *Sanatorio Sagrado Corazón, CABA, Argentina*

<sup>13</sup> *Hospital Regional de Río Gallegos, Río Gallegos, Argentina*

<sup>14</sup> *Sanatorio Boratti, Posadas, Argentina*

<sup>15</sup> *Hospital Muñoz, CABA, Argentina*

<sup>16</sup> *Hospital Argerich, CABA, Argentina*

<sup>17</sup> *Hospital Privado de Rosario, Rosario, Argentina*

<sup>18</sup> *Hospital Italiano de Buenos Aires, Infectious Diseases Section, CABA, Argentina*

<sup>19</sup> *Hospital Universitario Austral, Pilar Centro, Argentina*

<sup>20</sup> *Hospital Fernández, CABA, Argentina*

<sup>21</sup> *Hospital Italiano de Buenos Aires, Department of Research, CABA, Argentina*

<sup>22</sup> *Hospital de Clínicas, Montevideo, Uruguay*

<sup>23</sup> *Hospital Militar, Montevideo, Uruguay*

<sup>24</sup> *Hospital Italiano de Buenos Aires, Liver Unit, CABA, Argentina*